Effect of Low-dose and Standard-dose Aspirin on PGE₂ Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial.

ABSTRACT: Low-dose aspirin is recommended by the U.S. Preventive Services Task Force for primary prevention of colorectal cancer in certain individuals. However, broader implementation will require improved precision prevention approaches to identify those most likely to benefit. The major urinary metabolite of PGE₂, 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), is a biomarker for colorectal cancer risk, but it is unknown whether PGE-M is modifiable by aspirin in individuals at risk for colorectal cancer. Adults (N = 180) who recently underwent adenoma resection and did not regularly use aspirin or NSAIDs were recruited to a double-blind, placebo-controlled, randomized trial of aspirin at 81 or 325 mg/day for 8-12 weeks. The primary outcome was postinter

SUBMITTER: Drew DA 

PROVIDER: S-EPMC7541643 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature